WO2024256632 - PHARMACEUTICAL FORMULATIONS OF AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST COMPRISING A CYCLODEXTRIN
National phase entry is expected:
Publication Number
WO/2024/256632
Publication Date
19.12.2024
International Application No.
PCT/EP2024/066541
International Filing Date
14.06.2024
Title **
[English]
PHARMACEUTICAL FORMULATIONS OF AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST COMPRISING A CYCLODEXTRIN
[French]
FORMULATIONS PHARMACEUTIQUES UN AGONISTE DU RÉCEPTEUR DE L'AMYLINE ET UN AGONISTE DU RÉCEPTEUR GLP-1 COMPRENANT UNE CYCLODEXTRINE
Applicants **
NOVO NORDISK A/S
Novo Alle 1
2880 Bagsværd, DK
Inventors
KJELDSEN, Benjamin, Troest
Novo Alle 1
2880 Bagsværd, DK
HANSEN, Rosa, Rebecca, Erritzøe
Novo Alle 1
2880 Bagsværd, DK
CHRISTOFFERSEN, Stig
Novo Alle 1
2880 Bagsværd, DK
Priority Data
23179381.1
15.06.2023
EP
23180629.0
21.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1776 | |
| EPO | Filing, Examination | 6729 | |
| Japan | Filing | 533 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 3685 |
Total: 13330 USD
Abstract[English]
Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.[French]
L'invention divulgue une formulation pharmaceutique liquide préservée comprenant un agoniste du récepteur de l'amyline, un agoniste du récepteur GLP-1, une cyclodextrine comprenant des substitutions d'hydroxypropyle et un ou plusieurs conservateurs. Ladite coformulation peut être utilisée pour le traitement médical de sujets atteints de surpoids ou d'obésité, avec ou sans comorbidités associées; le diabète, avec ou sans comorbidités associées; et des maladies cardiovasculaires.